Comprehensive approaches to the diagnosis and treatment of HIV infection in the community: Can "Seek and Treat" really deliver?

Current Infectious Disease Reports

Volumn 13, Issue 1, 2011, Pages 68-74

  Conway, Brian ^a   Tossonian, Harout ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Combination antiretroviral therapy (cART); Hepatitis C virus (HCV); HIV; HIV Prevention Trials Network (HPTN); Prevention; Testing; Transmission

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CIRCUMCISION; COMORBIDITY; CONDOM; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DRUG TREATMENT FAILURE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL RESEARCH; MIXED INFECTION; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PILOT STUDY; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH SERVICE; THERAPY DELAY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 79551513601     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0151-y     Document Type: Article

References (50)

1. UNAIDS. 2008 report on the global AIDS epidemic. Geneva: Joint UN Programme on HIV/AIDS, 2008.
2. E Wood T Kerr BD Marshall, et al. 2009 Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study BMJ 338 b1649 10.1136/bmj.b1649 19406887
3. Marks G, Crepaz N, Janssen RS: Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 2006;20:1447-50.
4. LP Bamford PD Ehrenkranz MG Eberhart, et al. 2010 Factors associated with delayed entry into primary HIV medical care after HIV diagnosis AIDS 24 928 30 10.1097/QAD.0b013e328337b116 20154577
5. CW Dieffenbach AS Fauci 2009 Universal VCT and ART for prevention of HIV transmission JAMA 301 2380 2 1:CAS:528:DC%2BD1MXntFertrs%3D 10.1001/jama.2009. 828 19509386
6. C Bateman 2009 Treat all HIV-positive people and bury the pandemic in 14 years S Afr Med J 99 80 2 19418663
7. A Anema E Wood JS Montaner 2008 The use of highly active retroviral therapy to reduce HIV incidence at the population level CMAJ 179 13 4 18591515
8. JS Montaner R Hogg E Wood, et al. 2006 The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic Lancet 368 531 6 10.1016/S0140-6736(06)69162-9 16890841 (Pubitemid 44142776)
9. NS Padian SI McCoy JE Balkus JN Wasserheit 2010 Weighing the gold in the gold standard: challenges in HIV prevention research AIDS 24 621 35 10.1097/QAD.0b013e328337798a 20179575
10. C Dye CJ Watt DM Bleed, et al. 2005 Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence and deaths globally JAMA 293 2767 75 1:CAS:528:DC%2BD2MXltVCgu7o%3D 10.1001/jama.293.22.2767 15941807 (Pubitemid 40965089)
11. JG García-Lerma RA Otten SH Qari, et al. 2008 Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir PLoS Med 5 e28 10.1371/journal.pmed.0050028 18254653 (Pubitemid 351317659)
12. Achievements in public health 2006 Reduction in perinatal transmission of HIV infection-United States, 1985-2005 Morb Mortal Wkly Rep 55 592 597
13. J Stephenson 2010 Scientists explore use of anti-HIV drugs as a means to slow HIV transmission JAMA 303 1798 9 1:CAS:528:DC%2BC3cXmtV2hsrk%3D 10.1001/jama.2010.578 20460611
14. S Attia M Egger M Müller, et al. 2009 Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis AIDS 23 1397 404 10.1097/QAD.0b013e32832b7dca 19381076
15. D Donnell JM Baeten J Kiarie, et al. 2010 Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis Lancet 375 2092 8 10.1016/S0140-6736(10)60705-2 20537376
16. Sullivan P, Kayitenkore K, Chomba E, et al.: Reduction of HIV Transmission Risk and High Risk Sex while Prescribed ART: Results from Discordant Couples in Rwanda and Zambia. In: Program and abstracts of the16th Conference on Retroviruses and Opportunistic infections, February 8-11, 2009, Montreal, Canada.
17. TC Quinn MJ Wawer N Sewamkambo, et al. 2000 Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project study group N Engl J Med 342 921 9 1:STN:280:DC%2BD3c7otlWjsA%3D%3D 10.1056/ NEJM200003303421303 10738050 (Pubitemid 30177052)
18. FJ Palella Jr M Deloria-Knoll JS Chmiel, et al. 2003 HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata Ann Intern Med 138 620 6 12693883
19. RM Granich CF Gilks C Dye, et al. 2009 Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model Lancet 373 48 57 10.1016/S0140-6736(08)61697- 9 19038438
20. JS Montaner VD Lima R Barrios, et al. 2010 Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study Lancet 376 532 9 10.1016/S0140-6736(10)60936-1 20638713
21. Debeck K, Kerr T, Bird L, et al.: Injection drug use cessation and use of North America's first medically supervised safer injecting facility. Drug Alcohol Depend 2010 (Epub ahead of print).
22. M Das PL Chu GM Santos, et al. 2010 Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco PLoS One 5 e11068 10.1371/journal.pone.0011068 20548786
23. K Squires AL Pozniak G Pierone Jr, et al. 2003 Study 907 Team. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial Ann Intern Med 139 313 20 1:CAS:528:DC%2BD3sXnslGmtLs%3D 12965939
24. TD Hollingsworth RM Anderson C Fraser 2008 HIV-1 transmission, by stage of infection J Infect Dis 198 687 93 10.1086/590501 18662132
25. Centers for Disease Control and Prevention Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Morbidity and Mortality Weekly Report 2006;55:1-13.
26. LV Torian EW Wiewel KL Liu, et al. 2008 Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus Arch Intern Med 168 1181 7 10.1001/archinte.168.11.1181 18541826 (Pubitemid 351831401)
27. SH Mehta GD Kirk J Astemborski, et al. 2010 Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008 Clin Infect Dis 50 1664 71 1:CAS:528: DC%2BC3cXovFCmsbY%3D 10.1086/652867 20450418
28. B Conway J Grebely H Tossonian, et al. 2005 A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective Clin Infect Dis 41 S73 8 1:CAS:528:DC%2BD2MXmtValur0%3D 10.1086/429500 16265619 (Pubitemid 40863729)
29. PJ Dodd GP Garnett TB Hallett 2010 Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings AIDS 24 729 35 10.1097/QAD.0b013e32833433fe 20154580
30. DL Paterson S Swindells J Mohr, et al. 2000 Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 21 30 1:STN:280:DC%2BD3czit1altA%3D%3D 10877736
31. DR Bangsberg FM Hecht ED Charlebois, et al. 2000 Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population AIDS 14 357 66 1:CAS:528:DC%2BD3cXis1egu7s%3D 10.1097/00002030- 200003100-00008 10770537 (Pubitemid 30182431)
32. DR Bangsberg S Perry ED Charlebois, et al. 2001 Non-adherence to highly active antiretroviral therapy predicts progression to AIDS AIDS 15 1181 3 1:STN:280:DC%2BD3MzltFKhug%3D%3D 10.1097/00002030-200106150-00015 11416722 (Pubitemid 32549871)
33. B Spire GM Lucas MP Carrieri 2007 Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST) Int J Drug Policy 18 262 70 10.1016/j.drugpo.2006.12.014 17689374 (Pubitemid 47126278)
34. FL Altice DS Maru RD Bruce, et al. 2007 Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial Clin Infect Dis 45 770 8 1:CAS:528:DC%2BD2sXhtFahtrrF 10.1086/521166 17712763 (Pubitemid 47378892)
35. D Watson-Jones K Baisley M Rusizoka, et al. 2009 Measurement and predictors of adherence in a trial of HSV suppressive therapy in Tanzania Contemp Clin Trials 30 504 12 10.1016/j.cct.2009.07.002 19665587
36. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 97 1:CAS:528:DC%2BD2MXntVCisL0%3D 10.1056/NEJMra050100 16079372 (Pubitemid 41127293)
37. Tossonian H, Raffa J, Grebely J, et al.: Directly observed therapy (DOT) for the treatment of HIV-infection in injection drug users (IDUs): 2000-2005. In: Program and abstracts of XVI International AIDS Conference, August 13-18, 2006, Toronto, Canada.
38. Tossonian H, Raffa JD, Alenezi O, et al.: Use of once-daily raltegravir-based HAART in HIV-infected injection drug users. In: Program and abstracts of the 10th International Congress on Drug Therapy in HIV Infection, November 7-11, 2010, Glasgow, United Kingdom.
39. Cooper C, Tossonian H, La Porte C, et al.: Personal Communication. Submitted for presentation.
40. G Marks N Crepaz JW Senterfitt RS Janssen 2005 Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs J Acquir Immune Defic Syndr 39 446 53 10.1097/01.qai.0000151079.33935.79 16010168 (Pubitemid 41003791)
41. BD Marshall MJ Milloy T Kerr, et al. 2010 No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs AIDS 24 2271 8 10.1097/QAD.0b013e32833dd101 20683314
42. R Horton P Das 2008 Putting prevention at the forefront of HIV/AIDS Lancet 372 421 2 10.1016/S0140-6736(08)60882-X 18687463
43. MJ Alter 2006 Epidemiology of viral hepatitis and HIV co-infection J Hepatol 44 S6 9 10.1016/j.jhep.2005.11.004 16352363 (Pubitemid 43053865)
44. E Rosenthal D Salmon-Céron C Lewden, et al. 2009 Mortavic/Mortalité 2005 Study Group HIV Med 10 282 9 1:STN:280: DC%2BD1M3ptVyktQ%3D%3D 10.1111/j.1468-1293.2008.00686.x 19226410
45. I Bica B McGovern R Dhar, et al. 2001 Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection Clin Infect Dis 32 492 7 1:STN:280:DC%2BD38%2Fgs12kug%3D%3D 10.1086/318501 11170959 (Pubitemid 32173638)
46. Conway B, Gallagher L, Knight E, et al.: Treatment of Hepatitis C Virus Infection in Injection Drug Users (IDUs): An Update on a Multidisciplinary Program in Vancouver. In: Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010, Boston, USA.
47. SH Mehta A Cox DR Hoover, et al. 2002 Protection against persistence of hepatitis C Lancet 359 1478 1483 10.1016/S0140-6736(02)08435-0 11988247 (Pubitemid 34457766)
48. Conway B, Barrieshee A, Tossonian H, et al.: Hepatitis C Virus (HCV) Infection and Re-Infection among HCV and HIV/HCV-infected Injection Drug Users. In: Program and abstracts of the 10th International Congress on Drug Therapy in HIV Infection, November 7-11, 2010, Glasgow, United Kingdom.
49. • TLC-Plus: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States [HPTN 065]. Available at http://www.hptn.org/web documents/HPTN065/065Protocol- Version2-15Jul10.pdf. Accessed October 2010. The most rigorous and comprehensive approach to the evaluation of the seek and treat hypothesis that has yet been proposed, at least in the developed world.
50. Conway B, Raffa JD, Grebely J, et al.: Treatment of HIV Infection in Injection Drug Users: Directly Observed Therapy (DOT) and Self Administered Therapy (SAT). In: Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010, Boston, USA.